openPR Logo
Press release

Global Breast Cancer Vaccine Clinical Trial Insight

06-29-2017 09:36 AM CET | Health & Medicine

Press release from: Kuick Resarch

“Global Breast Cancer Vaccine Clinical Trial Insight” Report Highlight:

* Global Breast Cancer Vaccine Market Overview
* Global Breast Cancer Vaccine Clinical Pipeline by Company, Phase & Country
* Mechanism of Breast Cancer Vaccine & Personalized Cancer Vaccines
* Detailed Clinical Insight on Breast Cancer Vaccine Pipeline: 35 Vaccines
* Majority in PHASE-I Clinical Trial: 12 Vaccines
* Highest Clinical Phase is PHASE-III: 2 Vaccines (NeuVax & OBI-822)

Cancer vaccines have emerged viable option for treating multiple cancers which in the present day scenario do not have effective treatments. Therapeutic cancer vaccines and Prophylactic cancer vaccines are the two broad segments into which the cancer vaccines market is categorized. Therapeutic or Treatment vaccines are targeted at treating an existing cancer by strengthening the body’s natural defenses against the cancer while the Prophylactic or Preventive vaccines are used to prevent cancer from developing in healthy people. With the approval of the prostate cancer vaccine, Provenge by Dendreon, the field of cancer vaccines has received an unprecedented boost. Consequently, many companies are expected to enter this highly profitable emerging field of preventing, treating, and potentially curing the cancer.

In last few years, the peptide cancer vaccines have been demonstrating potential in clinical trials for the treatment of breast cancer. The high versatility and easy modification capabilities have made them widely acceptable among oncologists. They are sometimes developed to target over expressed receptors specific to the breast cancer cells. These vaccines stimulate a cancer patients' immune system to identify and eliminate breast cancer cells. Clinical trials have also shown the efficacy of peptide vaccines in shrinking breast cancer. This has encouraged the oncologists to develop better breast cancer vaccine for patients.

Download Report:

https://www.kuickresearch.com/report-Global-Breast-Cancer-Vaccine-Clinical-Trial-Insight.php

The development and deciphering of underlying principle of breast cancer vaccine will improve significantly driven by technological advancement occurred in recent years. Innovative products developed in this way will decrease the development time and will also help in cost arbitrage. Without cost effectiveness it would be difficult for pharmaceutical companies to compete and occupy substantial share in breast cancer market. However, it is expected that the cost of these vaccines would be high at the time of introduction which will subsequently decrease due to availability of other vaccines in same category.
It is most likely that the first breast cancer vaccines would be introduced in market in the next 3-5 years period. Clinical trials would be able to come with thoroughly checked version of products under investigation which would be able to provide higher levels of medical care to breast cancer patients. Most of the innovative products are at the final stages of clinical trials which are supposed to clear the targeted end points.

For Report Sample Contact: neeraj@kuickresearch.com or

visit: https://www.kuickresearch.com

Recent Publications:

* Global Cancer Immunotherapy Market & Clinical Trials Outlook 2022
* Global CAR T Cell Therapy Market & Clinical Trials Insight 2022
* Global Dendritic Cell Cancer Vaccine Market & Clinical Trials Outlook 2023
* Global Microcapsules Drug Delivery Market Opportunity Outlook 2022
* Global Controlled Drug Delivery Market & Clinical Trial Outlook 2022
* Global Cancer Antibody Drug Conjugates Market & Pipeline Insight 2022
* Global B Cell Lymphoma Market & Clinical Pipeline Insight 2022

Kuick Research is a market research and analytics company that provides targeted information for critical decisions at business, product and service levels. We are quick, predictive and known by the recommendations we have made in the past. Our result-oriented research methodology offers understanding of multiple issues in a short period of time and gives us the capability to keep you full with loads of practical ideas. By translating research answers into strategic insight and direction, we not only rate the success potential of your products and/or services, but also help you identify the opportunities for growth in new demographies and find ways to beat competition.

Neeraj Chawla
neeraj@kuickresearch.com
KuicK Research
Avanta Business Center 4th Floor,
Statesman House Barakhamba Road,
Connaught Place New Delhi – 110 001, India
+91-11-47067990

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Global Breast Cancer Vaccine Clinical Trial Insight here

News-ID: 601342 • Views:

More Releases from Kuick Resarch

Lumakras Drug Clinical Insight and Sales Forecast 2026
Lumakras Drug Clinical Insight and Sales Forecast 2026
"Lumakras Drug Clinical Insight and Sales Forecast 2026" Report Highlights: * NSCLC Targeting Lumakras Market Opportunity (US$ Million) * Colorectal Cancer Targeting Lumakras Market Opportunity (US$ Million) * Pharmacokinetics of Lumakras (Sotorasib) * Dosage, Patent and Price Analysis * Lumakras Ongoing Clinical Trials * Global KRAS Protein Inhibitors Clinical Trials Download Report: https://www.kuickresearch.com/report-lumakras-sotorasib-sales-forecast-fda-approved-kras-inhibitor-clinical-trials-non-small-cell-lung-cancer-nslc-g12c-mutation-c30h30f2n6o3-ras-gtpase The rising burden of cancer and the increasing cancer mortality rates possesses an unmet need for the development of novel therapies in the management
Global EZH2 Inhibitor Market Opportunity, Sales and Clinical Trials Insight 2026
Global EZH2 Inhibitor Market Opportunity, Sales and Clinical Trials Insight 2026
"Global EZH2 Inhibitor Market Opportunity, Sales and Clinical Trials Insight 2026" Report Highlights: * Global EZH2 Inhibitor Market Opportunity > US$ 1.2 Billion by 2026 * Tazverik (Tazemetostat) First Approved EZH2 Inhibitor Drug * Dosage, Price and Sales Analysis of Tazverik * Tazverik Sales Opportunity > US$ 900 Million by 2026 * Tazverik Sales Forecast 2021 Till 2026 * EZH2 Inhibitor Clinical Pipeline Overview By Company, Indication and Phase * EZH2 Inhibitor in Clinical Trials: 7 Drugs Download
Global Bispecific Antibody Market Opportunity, Drug Sales, Price and Clinical Trials Insight 2028
Global Bispecific Antibody Market Opportunity, Drug Sales, Price and Clinical Tr …
"Global Bispecific Antibody Market Opportunity, Drug Sales, Price and Clinical Trials Insight 2028" Report Highlights: * Global Bispecific Antibody Market Opportunity: > US$ 20 Billion * Global Bispecific Antibody Market Growth Rate: 100% CAGR (2016 -2021) * Approved Bispecific Antibodies In Market: 4 Antibodies * Detailed Market Sales and Trends Insight Till 2028 * Quarterly and Yearly Sales Insight Of Approved Antibodies Till Q1 2022 * Global and Regional Market Analysis * Approved Drug Sales
Global Fibroblast Growth Factor Receptor Inhibitor Drug Market Opportunity and Clinical Trials Insight 2026
Global Fibroblast Growth Factor Receptor Inhibitor Drug Market Opportunity and C …
"Global Fibroblast Growth Factor Receptor Inhibitor Drug Market Opportunity and Clinical Trials Insight 2026" Report Highlights: * Global FGFR Inhibitors Market Opportunity: > USD 4 Billion by 2026 * Role of FGFR Inhibitors in Cancer Therapy * Global FGFR Market Assessment (US$) by Region and Cancer Type Clinical and Sales Insight on Approved FGFR Inhibitors: 3 (Belvesra, Pemazyre and Truseltiq) * Dosage and Drug Price Insight on Approved FGFR Inhibitors * Comprehensive Clinical Trials Insight

All 5 Releases


More Releases for Clinical

Clinical Laboratory Market in Indonesia, Clinical Laboratory Industry in Indones …
"Increase in healthcare expenditure from the Indonesian government has driven the growth of clinical laboratory market in Indonesia." Increase in Healthcare Awareness: Largely driven by increase in healthcare spending by aging population (~$ 260 per person by 2050), rising income levels, rising awareness for preventive testing, advanced healthcare diagnostic tests offerings, and central government's healthcare measures. Developments in Testing and Preference for Evidence based testing: There is also a rising number
Clinical solutions
Are you spending more time with yellow files than with patients? Healthbridge can change that with our intuitive and easy to use clinical platform that is designed specifically for the medical practitioner at the practice. smaller2 Easily access patient information Cloud-based technology enables you to store rich clinical information that can be easily accessed as and when you need it. Medical billing software innovation Become a paperless practice Create scripts, sick notes, and clinical notes electronically. Plus, have
Clinical Research and Clinical Trials Summit
Clinical Research 2019 has been designed in an interdisciplinary manner with a multitude of tracks to choose from every segment and provides you with a unique opportunity to meet up with peers from both industry and academia and establish a scientific network between them. We cordially invite all concerned people to come join us at our event and make it successful by your participation. This is the premier interdisciplinary forum for
Paediatric Clinical Trial Conference - When designing a Paediatric clinical tria …
Press Release – 12.02.2018 When designing a Paediatric clinical trial, a paediatric investigation plan (PIP) is a development plan aimed at ensuring that the necessary data are obtained through studies in children, to support the authorisation of a medicine for children. All applications for marketing authorisation for new medicines have to include the results of studies as described in an agreed PIP, unless the medicine is exempt because of a deferral
Clinical Communication
According to a recent market report published by Persistence Market Research titled “Clinical Communication and Collaboration Market: Global Industry Analysis (2012–2016) and Forecast (2017–2025),” revenue from the global clinical communication and collaboration market was US$ 138.5 Mn in 2012 and US$ 214.8 Mn in 2016, representing a CAGR of 11.6% from 2012 to 2016. This revenue growth is attributed to addition of new features in clinical communication and collaboration solutions.
E-Clinical Trial Solutions Market To Accelerating Clinical Development Technolog …
The study of the "Global e-Clinical Trial Solutions Market" provides the market size information and market trends along with the factors and parameters impacting it in both short and long term. The study ensures a 360° view, bringing out the complete key insights of the industry. The Global e-Clinical Trial Solutions Market Research Report Forecast 2017-2021 is a valuable source of insightful data for business strategists. It provides the e-Clinical